<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126197">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02082574</url>
  </required_header>
  <id_info>
    <org_study_id>AMR_2013-6</org_study_id>
    <nct_id>NCT02082574</nct_id>
  </id_info>
  <brief_title>Prevalence of CSVD Among Patients Infected With HIV-1</brief_title>
  <acronym>MICROBREAK1</acronym>
  <official_title>Prevalence of Cerebral Small Vessel Disease (CSVD)Among Patients Infected With HIV-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cerebral small vessel disease (CSVD) is a major cause of cognitive impairment and disability
      in the general population, secondary to the accumulation of asymptomatic elementary lesions.
      CSVD is directly correlated with age and cardiovascular risk factors and therefore would be
      challenging in term of public health care in the future. While HIV patients share the same
      cardiovascular risk factors and they are often diagnosed with cognitive impairment and
      frailty, CSVD has not been yet described in this population.

      The global aim is to compare  the prevalence of  CSVD in a well controlled HIV+ population
      compared to HIV- controls matched with age and sex.

      500 HIV+ patients and 250 age- and sex- matched controls will undergo a screening of the
      CSVD with a 10 minutes MRI (FLAIR and T2*).

      Prevalence of the CSVD will be compared between HIV+ patients and controls. General and
      HIV-specific parameters from their electronic medical records will be compared between
      HIV+/CSVD+ and HIV+/CSVD- patients.

      We are expecting to prove that CSVD is more frequent in HIV+ population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Cerebral small vessel disease</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cerebral small vessel disease detected with MRI</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>HIV Seropositivity</condition>
  <arm_group>
    <arm_group_label>patients</arm_group_label>
    <description>HIV infected for more than 5 years, aged over 50, treated with ARV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>non HIV (matched for age and gender)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        HIV patients over 50 years old, infected for at least 5 years, treated with antiretroviral
        (ARV) therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age over 50

          -  chronic HIV seropositive patient infected for at least 5 years

          -  treated with any antiretroviral (ARV) therapy

          -  plasmatic HIV viral load &lt;40 copies/ml for at least one year with one authorized blip
             &lt; 1000 copies/ml per year

        Exclusion Criteria:

          -  patient treated with ARV showing a viral load &gt;40 copies/ml at two consecutive tests

          -  HIV patient non treated with ARV
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine MOULIGNIER, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation Ophtalmologique Adolphe de Rothschild</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anoine MOULIGNIER, Dr</last_name>
      <phone>+33 148 036 778</phone>
      <email>amoulignier@fo-rothschild.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>March 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
